Immatics N.V. is a clinical-stage biopharmaceutical company that develops personalized cancer immunotherapies using proprietary platforms combining tumor-infiltrating lymphocyte (TIL) and engineered T-cell receptor (TCR) technologies to identify patient-specific tumor mutations and generate customized immune responses for solid tumors and hematologic malignancies. The company generates revenue through collaboration and licensing agreements with pharmaceutical partners, academic medical centers, and research institutions, while serving the global oncology market with support from third-party contract manufacturers. As a clinical-stage developer, Immatics incurs significant research and development expenses and relies on equity financing and milestone payments from its strategic partnerships to fund its ongoing clinical programs and manufacturing capabilities.